Table 1.

In Vitro Antibacterial Activity of the Target Compounds at 100 μg/mL ^a.

	b Psa		Xac		Xoo
Compd.	100 μg/mL	50 μg/mL	100 μg/mL	50 μg/mL	100 μg/mL	50 μg/mL
D1	37.0 ± 0.6	11.0 ± 0.2	14.7 ± 2.7	11.1 ± 2.9	14.9 ± 1.0	9.6 ± 2.1
D2	12.6 ± 0.2	9.0 ± 0.3	25.7 ± 0.3	16.8 ± 1.4	6.9 ± 0.4	1.6 ± 0.4
D3	31.6 ± 0.7	25.7 ± 0.5	32.7 ± 1.3	11.7 ± 5.3	5.7 ± 0.2	3.5 ± 1.6
D4	9.0 ± 1.6	7.2 ± 0.3	28.6 ± 2.1	20.0 ± 1.4	6.0 ± 1.3	1.4 ± 0.8
D5	42.2 ± 0.9	30.4 ± 0.9	9.4 ± 1.7	4.2 ± 1.5	16.8 ± 3.2	9.2 ± 1.8
D6	10.8 ± 0.7	8.5 ± 0.7	49.7 ± 1.4	31.3 ± 0.9	86.5 ± 1.8	76.7 ± 0.7
D7	10.2 ± 0.2	9.42 ± 0.3	23.4 ± 0.9	11.1 ± 0.9	21.5 ± 1.1	16.4 ± 1.5
D8	10.7 ± 1.1	8.7 ± 0.6	27.6 ± 0.2	17.2 ± 0.3	19.6 ± 0.9	15.3 ± 1.9
D9	38.8 ± 0.2	22.8 ± 0.4	39.5 ± 2.2	20.8 ± 3.5	4.3 ± 0.2	3.6 ± 0.2
D10	18.6 ± 0.4	12.8 ± 0.5	8.0 ± 2.7	7.0 ± 1.6	28.3 ± 1.9	19.2 ± 1.0
D11	16.0 ± 0.1	11.6 ± 0.5	12.9 ± 0.7	10.8 ± 0.3	14.4 ± 1.1	10.6 ± 0.2
D12	13.0 ± 2.0	12.1 ± 0.4	19.0 ± 0.4	17.8 ± 1.1	15.3 ± 0.0	7.7 ± 0.1
D13	12.5 ± 0.9	11.6 ± 0.3	44.2 ± 0.6	24.3 ± 0.3	12.1 ± 0.6	9.5 ± 0.7
D14	8.4 ± 0.4	8.0 ± 0.54	30.4 ± 3.1	18.5 ± 2.4	14.2 ± 1.1	11.8 ± 1.7
D15	14.9 ± 0.5	9.4 ± 0.3	19.5 ± 2.8	11.8 ± 3.0	15.2 ± 0.5	9.3 ± 1.5
D16	9.7 ± 0.6	9.1 ± 0.6	34.7 ± 0.7	28.0 ± 2.1	15.6 ± 2.5	7.0 ± 5.0
D17	16.7 ± 0.9	11.8 ± 0.8	9.9 ± 2.4	8.0 ± 0.8	12.1 ± 3.2	5.1 ± 3.9
D18	12.4 ± 0.3	11.5 ± 0.2	31.0 ± 0.5	29.6 ± 1.4	16.4 ± 3.4	11.2 ± 1.4
D19	18.0 ± 0.9	13.4 ± 0.63	20.6 ± 0.9	16.5 ± 0.7	12.0 ± 1.1	7.8 ± 0.9
TC c	65.8 ± 0.3	20.0 ± 0.2	80.1 ± 3.4	53.0 ± 0.3	85.8 ± 0.9	62.1 ± 0.7
BT c	26.5 ± 0.2	24.8 ± 0.5	35.6 ± 4.7	27.4 ± 4.0	78.2 ± 0.6	57.4 ± 1.0
Myr. c	18.5 ± 0.3	11.5 ± 0.2	22.9 ± 1.3	20.3 ± 1.9	32.0 ± 4.5	15.1 ± 0.3

^a Values are mean ± SD of three replicates. ^b Xac (Xanthomonas axonopodis pv. Citri), Psa (Pseudomonas syringae pv. Actinidiae) and Xoo (Xanthomonas oryzae pv. Oryzae); ^c BT (bismerthiazol), TC (thiodiazole copper) and Myr. (myricetin).